Ultragenyx Pharmaceutical (RARE) News Today

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has experienced mixed analyst activity today. A series of downward earnings revisions and a reduced price target have pressured the stock, while a few upgrades to quarterly forecasts offer modest support.

• Positive Sentiment: HC Wainwright raised its Q3 2025 EPS estimate to ($1.15) from ($1.25) and maintained a Buy rating with an $80 price target.
• Positive Sentiment: Leerink Partnrs increased its Q3 2025 EPS forecast to ($1.31) from ($1.39).
• Neutral Sentiment: Ultragenyx’s Q2 2025 earnings call transcript was released, offering fresh management commentary on the commercial rollout and pipeline progress. Q2 2025 Earnings Call Transcript
• Negative Sentiment: Cantor Fitzgerald trimmed its FY 2025 EPS estimate to ($5.19) from ($5.15) and lowered its price target from $112 to $105. Cantor Fitzgerald Price Target Cut
• Negative Sentiment: William Blair reduced its Q4 2026 EPS forecast to $0.94 from $0.99, despite an Outperform rating and $65 target. William Blair Lowers Q4 2026 Estimates
• Negative Sentiment: Wedbush cut its FY 2028 EPS projection to $0.28 from $0.31 and kept a Neutral rating with a $34 price target.